LEASE THE EXCHANGE KRE EXCHANGE OWNER LLC a Delaware limited liability company as Landlord, and VIR BIOTECHNOLOGY, INC., a Delaware corporation As Tenant. 1800 Owens Street, San Francisco, California North Tower Floors 8, 9, 10, 11 and 12Lease Agreement • February 28th, 2022 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between KRE EXCHANGE OWNER LLC, a Delaware limited liability company (“Landlord”), and VIR BIOTECHNOLOGY, INC., a Delaware corporation (“Tenant”).
AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc effective March 16, 2018, as amended, and bearing Investment ID INV-009475/OPP1182112 Amendment Purpose: No Cost...Grant Agreement • February 28th, 2022 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.Strategic Relationship Agreement • February 28th, 2022 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Washington
This amended and restated letter agreement (including all appendices hereto, this “Letter Agreement”) is entered into as of January 12, 2022 by and between the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, and Vir Biotechnology, Inc., a Delaware corporation (the “Company”) and is effective on the Amendment Effective Date (as defined below). This Letter Agreement amends and restates in its entirety the letter agreement entered into as of December 23, 2016 (“Effective Date”) by and between the Foundation and the Company (the “Prior Agreement”), in connection with the investment by the Foundation of twenty million dollars ($20,000,000.00) in the Company through the purchase of (i) ten million dollars ($10,000,000.00) of shares of Series A-1 Preferred Stock, par value $0.0001, of the Company (the “Series A-1 Shares”) at a purchase price of [***] per share and (ii) ten million dollars ($10,000,000.00) of shares of
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 28th, 2022 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Stock Purchase Agreement (“Agreement”) is entered into as of January 12, 2022 (the “Execution Date”), by and between the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation having an office at 500 5th Ave N, Seattle, WA 98109 (the “Foundation”), and Vir Biotechnology, Inc. a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1.
